GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹10 Cr | ₹21 Cr | ₹16 Cr | ₹22 Cr | ₹13 Cr |
What is the latest Contingent Liabilities ratio of GLAND PHARMA ?
| Year | Contingent Liabilities |
|---|---|
| Mar2026 | ₹10 Cr |
| Mar2025 | ₹21 Cr |
| Mar2024 | ₹16 Cr |
| Mar2023 | ₹22 Cr |
| Mar2022 | ₹13 Cr |
How is Contingent Liabilities of GLAND PHARMA Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹10 Cr | -52.68 | |
| Mar2025 | ₹21 Cr | 37.24 | |
| Mar2024 | ₹16 Cr | -29.41 | |
| Mar2023 | ₹22 Cr | 72.94 | |
| Mar2022 | ₹13 Cr | - | |
Compare Contingent Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹50,653.4 Cr | 6.8% | 3.2% | 59.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹420,483.0 Cr | -3.2% | -7.8% | 9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹249,248.0 Cr | 1% | 0.9% | 67.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹177,822.0 Cr | -1.8% | -4.8% | 32.2% | Stock Analytics | |
| CIPLA | ₹105,427.0 Cr | -3.1% | -6.5% | -12.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,492.3 Cr | -1.7% | 3.1% | -3.5% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | 6.8% |
3.2% |
59.2% |
| SENSEX | -1.2% |
-6.4% |
-10.8% |
You may also like the below Video Courses